AstraZeneca is hopping on the pickleball craze for the latest iteration of its Stepping Back Out campaign for asthma ...

A Phase II investigator-led trial investigating AstraZeneca’s Fasenra (benralizumab) treating eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD) has ...

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

AstraZeneca’s asthma drug Fasenra also works in a group of rare diseases that can lead to potentially fatal organ damage, a mid-stage trial has shown. Results of the phase 2 trial, published in ...

Revenues increased across all segments, with sales of most of the key drugs, including Tagrisso, Fasenra, Farxiga, Lynparza and Symbicort, beating estimates. The British drugmaker said that the ...